CCL19 and neoplasm: Functional studies have shown the anti-tumor activity of MIP-3β, resulting from its ability to increase the number of anti-tumor immune cells [70], to suppress angiogenesis [68], and to increase the expression and secretion of IFN-γ and IL-12 [71].